Esperion, Otsuka Report Primary Endpoint Was Achieved In Phase 3 Trial In Japan For Bempedoic Acid As Potential Treatment For Patients With Hypercholesterolemia
Esperion, Otsuka Report Primary Endpoint Was Achieved In Phase 3 Trial In Japan For Bempedoic Acid As Potential Treatment For Patients With Hypercholesterolemia
The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan.
該試驗顯示了本培多酸的主要終點具有統計學意義的結果，並強調了其對日本患者的潛在未來價值。
In the preliminary results, the percentage change from baseline in LDL-C at Week 12, the primary endpoint, was -25.25%% in the group receiving bempedoic acid placebo group and -3.46% in the placebo group, demonstrating positive outcomes with statistical significance compared to placebo (p<0.01).
在初步結果中，作爲主要終點的第12周低密度脂蛋白C與基線相比的百分比變化百分比在接受本培多酸安慰劑組中爲-25.25％，安慰劑組爲-3.46％，顯示出與安慰劑相比具有統計學意義的積極結果（p
In 2020, Otsuka acquired exclusive development and commercialization rights for bempedoic acid in Japan from Esperion and is currently developing it domestically.
2020年，大冢從Esperion手中獲得了本美多酸在日本的獨家開發和商業化權，目前正在國內進行開發。